Calcium Antagonists: An Overview

Giles, Thomas D.
August 1982
Angiology;Aug1982, Vol. 33 Issue 8, p489
Academic Journal
Introduction of the calcium antagonists for clinical use in the United States constitutes a major advance in expanding the pharmacologic armamentarium available to the practicing physician for treating patients with heart disease. Cautious optimism should be the watchword until clinical use indicates the true benefit and nature of undesirable effects of the calcium antagonists.


Related Articles

  • Amlodipine reduces CV events in CAD patients with normal BP.  // Formulary;Jan2005, Vol. 40 Issue 1, p11 

    Reports on the link of calcium antagonist amlodipine to the reduction of cardiovascular events in patients with coronary artery disease. Benefit of the decrease of blood pressure on atherosclerosis; Comparison of intravascular ultrasound with atheroma volume.

  • Study backs preventive use of long-acting CCBs. James, Laura // GP: General Practitioner;4/17/2009, p13 

    The article reports on the randomised controlled trials of long-acting calcium-channel blockers (CCBs) in patients with coronary artery disease conducted between 1966 and 2008. Researchers from the Columbia University College of Physicians and Surgeons have demonstrated that long-acting CCBs can...

  • Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or nonblack patients.  // ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p63 

    This article presents information on a clinical study according to which amlodipine or lisinopril was not better than chlorthalidone for reducing cardiovascular disease (CVD) risk in hypertensive black or nonblack patients. The study explored whether in black or nonblack patients with...

  • Selected cardiovascular agents.  // Formulary;Jan2005, Vol. 40 Issue 1, p32 

    Presents information on selected cardiovascular agents available in the United States. Azimilide; Dronedarone; Tecadenoson; Tedisamil; Enoximone; Oxypurinol; Tolvaptan.

  • LONG TERM MEDICAL TREATMENT OF STABLE CORONARY DISEASE. Shavelle, David M. // Heart;Nov2007, Vol. 93 Issue 11, p1473 

    The article provides information on the medical treatment for stable coronary artery disease (CAD). The medical management of patients with stable CAD include the use of aspirin, beta-blockers, nitrates and statins. Calcium channel blockers can be added if patients remain symptomatic or used...

  • Update on Quinidine and Procainamide. Cohen, Martin N. // Angiology;Jul1982, Vol. 33 Issue 7, p454 

    The article presents an update on Quinidine and Procainamide. Arrhythmia understanding and management is participating in the explosion of medical information and investigational techniques. New drugs are being introduced, such as disopyramide, verapamil, tocainide, mexiletine, aprindine, and...

  • ARB outperforms calcium antagonist in secondary stroke prevention.  // Geriatrics;Apr2005, Vol. 60 Issue 4, p16 

    The article informs that angiotensin receptor blocker, eprosartan, is associated with fewer adverse cardiovascular or cerebrovascular events, compared with the calcium antagonist, nitrendipine, in hypertensive patients with a recent history of stroke. In the Morbidity and Mortality after Stroke...

  • Tildiem. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p747 

    An encyclopedia entry for "Tildiem," which refers to a brand name for calcium channel blocker diltiazem, is presented.

  • COER Verapamil Is Ineffective in Preventing CV Disease. Wellbery, Caroline // American Family Physician;12/1/2003, Vol. 68 Issue 11, p2262 

    Presents an abstract of the study "Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial," by H.R. Black et al., from the April 23/30, 2003 issue of the "Journal of the American Medical Association."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics